MedPlus Health Services Limited's Board of Directors has approved the incorporation of a wholly owned subsidiary dedicated to Corporate Social Responsibility activities. The decision was taken during the board meeting held on March 16, 2026, marking a strategic step towards structured CSR implementation.

Board Meeting Details

The board meeting commenced at 11:00 A.M and concluded at 4:50 P.M on March 16, 2026. The primary agenda involved approving the incorporation of a Private Limited Company as a Wholly Owned Subsidiary under Section 8 of the Companies Act, 2013.

Subsidiary Structure and Purpose

The new subsidiary will be established exclusively for undertaking CSR activities, operating as a not-for-profit company. Key details of the subsidiary structure include:

Financial and Regulatory Framework

The subsidiary will be capitalized through subscription to share capital at face value. The company name will be finalized upon approval by the Registrar of Companies Hyderabad. Necessary approvals will be obtained from the Registrar of Companies and other relevant authorities as required.

Compliance and Disclosure

MedPlus Health Services Limited will furnish requisite disclosures to stock exchanges upon incorporation of the wholly owned subsidiary, as mandated under SEBI Listing Regulations. The company has committed to maintaining transparency in accordance with SEBI Master Circular for listed entities dated January 30, 2026.

Corporate Governance

The decision reflects the company's commitment to structured corporate social responsibility initiatives through a dedicated subsidiary framework. This approach allows for focused management of CSR activities while maintaining compliance with regulatory requirements under Section 8 of the Companies Act, 2013.

Source: None/Company/INE804L01022/3b736750-1189-4ad4-84cb-e1181b11eea4.pdf

MedPlus Health Services Limited has informed stock exchanges about additional regulatory actions taken against its subsidiary company's retail pharmacy operations. The healthcare retailer disclosed that Optival Health Solutions Private Limited, a subsidiary, has now received multiple drug license suspension orders from state drug control authorities across different locations.

Regulatory Actions Across Multiple States

The subsidiary has faced enforcement actions from drug control administrations in Karnataka, Telangana, and Andhra Pradesh. All suspension orders were issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Updated Financial Impact Assessment

The company has quantified the potential financial impact of these regulatory actions. With the latest suspension order received on March 14, 2026, the combined potential revenue loss across all affected stores has increased significantly. The newest Karnataka store suspension at Bidadi Bus stand carries the highest individual financial impact of Rs 2.88 lacs despite being a two-day suspension period.

Latest Regulatory Compliance Disclosure

MedPlus Health Services made the latest disclosure under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company received the most recent suspension order on March 14, 2026, and reported the matter to stock exchanges on March 15, 2026. Company Secretary and Compliance Officer Manoj Kumar Srivastava signed the regulatory filing.

Documentation and Transparency

The company has committed to making complete details available on its official website at www.medplusindia.com . The information will also be accessible through BSE Limited and National Stock Exchange of India websites, ensuring transparency for all stakeholders and regulatory compliance. The latest filing follows SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.